Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE
- PMLiVE

Pharmaceutical Market Europe – July/August 2014

In this issue we talk with Anssi Pulkkinen from Roche Diagnostics, Finland

- PMLiVE

Pharmaceutical Market Europe – June 2014

Allergan’s Paul Navarre and Paul Boland tell us about creating a culture of growth and we take a look at the Sunshine Act, diabetes and marketing in China and the...

- PMLiVE

Pharmaceutical Market Europe – May 2014

AstraZeneca’s Susan Galbraith - the company’s VP of oncology talks about AZ’s pipeline prospects

- PMLiVE

Pharmaceutical Market Europe – April 2014

MSD’s Bruno Strigini - the company’s president, Europe and Canada discusses adapting to a new market reality

- PMLiVE

Pharmaceutical Market Europe – March 2014

Mundipharma's Georg Toufar - the company’s chief marketing officer on the benefits of having a smaller, more concentrated focus

- PMLiVE

Pharmaceutical Market Europe – February 2014

Ferring’s president explains his company's approach to ‘controlled entrepreneurship’

- PMLiVE

Pharmaceutical Market Europe – January 2014

Sanofi’s SVP of corporate communications Laure Thibaud talks about her mission to build a communications team fit for the modern age

- PMLiVE

Pharmaceutical Market Europe – December 2013

The German HTA body’s drug assessment department head talks about taking a pragmatic approach to comparing medicines

- PMLiVE

Pharmaceutical Market Europe – November 2013

Lilly’s chief scientific officer for neurodegenerative diseases Dr Mike Hutton talks about the future for Alzheimer’s research

- PMLiVE

Pharmaceutical Market Europe – October 2013

Boehringer’s Allan Hillgrove talks access, partnerships and China

- PMLiVE

Pharmaceutical Market Europe – September 2013

Ariad’s Harvey Berger and Timothy Clackson discuss building a sustainable biotech business and following their own path

- PMLiVE

Pharmaceutical Market Europe – July/August 2013

Senior vice president of global research at UCB discusses the importance of patient-centricity, the value of collaboration and why full data transparency is problematic